Mylan Announces Final FDA Approval for Azithromycin Tablets

PITTSBURGH, May 31 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Azithromycin Tablets, 250 mg and 500 mg.

Azithromycin Tablets are the generic version of Pfizer's Zithromax® Tablets. Azithromycin Tablets had U.S. sales of approximately $886 million for the 12 months ending March 31, 2007, for the same strengths.

This product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.

CONTACT: Patrick Fitzgerald or Kris King, both for Mylan Laboratories
Inc., +1-724-514-1800
Web site: http://www.mylan.com